Soryuan Bio has been granted a new drug to treat Alzheimer's disease

recently, precision medicine company Soyuan Bio announced that it has obtained authorization from Finland's Orion Corporation to treat ORM-12741, a new drug for Alzheimer's disease.the global rights to the development, manufacture and commercialization of ORM-12741.about ORM-12741 ORM-12741 is a selective, powerful, brand new antagonist with a target of α-2C epinephrine ligands (AR), which may be effective for psychotic disorders such as Alzheimer's disease, schizophrenia and depression., more than 540 patients in 11 clinical studies have taken ORM-12741, confirming the drug's safety and tolerance. A Phase IIa study of ORM-12741 was presented at the 65th Annual Meeting of the American Academy of Neurology (AAN).the study showed that patients who used ORM-12741 had a 4 percent improvement in memory scores over 12 weeks, while the placebo group had a 33 percent improvement. THE orM-12741 has a particularly beneficial effect on situational memory. (Drug Information Network)